Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
In comparison to other psychedelics such as psilocin, LSA and ayahuasca, 1P-LSD is significantly more stimulating and fast paced in terms of the specific style of thought stream produced and contains a large number of potential effects.
The visual geometry of 1P-LSD can be described as more similar in appearance to that of 2C-B or 2C-I than psilocin, LSA or DMT. It can be comprehensively described as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, non-immersive in depth and consistent in intensity. At higher dosages, this substance is Level 8A dominant but is also capable of inducing 8B geometry under the right circumstances.
1P-LSD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
1P-LSD is considered non-addictive with low abuse potential. Animal studies with LSD show no self-administration behavior, indicating it lacks the pharmacology to initiate or maintain dependence. The desire to use can actually decrease with repeated use, making it largely self-regulating.
Virtually no withdrawal syndrome has been reported when chronic use of LSD is stopped, and 1P-LSD is assumed to share these properties. No physical dependence develops with use.
1P-LSD has no known toxic dose. Based on its similarity to LSD, it is assumed to be physiologically well-tolerated with extremely low toxicity relative to dose. There are relatively few physical side effects reported following acute exposure.
1P-LSD may act as a trigger for those with underlying mental disorders. Individuals with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of supervised medical settings. Higher doses increase the risk of adverse psychological reactions including anxiety, delusions, and panic attacks.
Seizures are rare but have been reported, with the likelihood largely extrapolated from LSD use. Risk primarily affects those who are genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
1P-LSD emerged on the online research chemical market in late 2014 and early 2015, representing the first widely available 1-acylated lysergamide derivative. The compound was first synthesized by Lizard Labs, a Netherlands-based research chemical laboratory that had already established a reputation…
Not scheduled under the UN Convention on Psychotropic Substances
Classified as a controlled substance under national drug legislation.
Not specifically listed in the Controlled Drugs and Substances Act. However, sale or possession for human consumption could potentially be prosecuted under analogue provisions.
Classified as a controlled substance since January 1, 2014.
Controlled as a Schedule I substance since June 1, 2017.
Listed as a controlled substance under national drug legislation.
Classified as a Schedule I controlled substance under Italian drug legislation.
Controlled as a structural analogue of LSD following an amendment to drug scheduling that took effect June 1, 2015. Not explicitly named but covered under analogue provisions.
Classified as a controlled substance since February 14, 2013.
Prohibited since 2017 as a derivative of LSD under national drug control laws.
Specifically scheduled following its emergence as a designer drug. Prohibition took effect January 26, 2016.
Prohibited under national drug control legislation since February 2016.
Not explicitly scheduled under the Controlled Substances Act. However, as a prodrug of LSD, possession and sale intended for human consumption may be prosecuted under the Federal Analogue Act, which treats substantially similar compounds as Schedule I substances.
Not explicitly scheduled but may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz) as a structural analogue of LSD, making supply for human consumption potentially illegal.
Listed as a prohibited substance under national drug control legislation.
Explicitly named on the list of controlled substances as of August 25, 2015.
Classified as a controlled substance since November 15, 2018.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import for market distribution, administration to others, and trading are criminal offenses. Personal possession is prohibited but not subject to criminal penalty.
Listed as a controlled substance under national drug control laws.
Explicitly named on the list of controlled substances since September 21, 2015.
Listed as a controlled substance under national drug legislation.
Classified as a Class A controlled substance, carrying severe penalties for possession, trafficking, and distribution.
Explicitly named under Verzeichnis E of controlled substances since December 2015.
Production, supply, and import prohibited under the Psychoactive Substances Act 2016, which came into effect May 26, 2016. This blanket legislation covers psychoactive substances not specifically exempted.
13 sources cited
